What is Amili?
Amili operates at the intersection of biotechnology and personalized health, maintaining Southeast Asia's inaugural gut microbiome transplant bank. By leveraging its world-class multi-ethnic Asian gut microbiome database, the company provides actionable insights through its integrated platform, which encompasses AMILI Analytics, AMILI Health, and AMILI Biosciences. The firm serves a diverse ecosystem of stakeholders, including pharmaceutical enterprises, healthcare professionals, and research institutions, effectively bridging the gap between complex biological data and consumer-facing health solutions. Its market position is defined by its unique ability to translate microbiome functionality into tangible health outcomes, setting a new standard for precision medicine in the region.
How much funding has Amili raised?
Amili has raised a total of $10.5M across 1 funding round:
Series A
$10.5M
Series A (2022): $10.5M with participation from Vulcan Capital Management, TVM Capital Healthcare Partners, and Pruksa Real Estate Public Company Limited
Key Investors in Amili
Vulcan Capital Management
A diversified private equity firm that leverages extensive market knowledge to target middle-market assets and generate significant returns for institutional investors.
TVM Capital Healthcare Partners
An emerging markets-focused healthcare private equity firm specializing in growth capital for digital health, pharmaceuticals, and medical diagnostics.
Pruksa Real Estate Public Company Limited
A prominent Thailand-based property developer and manager that has diversified its investment portfolio to include strategic stakes in high-growth healthcare technology.
What's next for Amili?
With this major enterprise-level funding, Amili is positioned to accelerate its research and development pipeline and expand its footprint in the global health-tech landscape. The strategic deployment of this capital will likely focus on enhancing the predictive capabilities of its analytics platform and scaling its personalized product offerings. As the company transitions into its next phase of growth, it is expected to deepen its collaborations with pharmaceutical entities, further validating its microbiome-based interventions. By maintaining its focus on data-driven health solutions, Amili is well-equipped to navigate the complexities of the biotech sector while delivering long-term value to its investors and stakeholders in the evolving landscape of personalized medicine.
See full Amili company page
